In This Issue
- Clinical Practice Spotlight: Preparing for Blinatumomab and CAR T-cell Therapies - Blinatumomab is a bispecific CD19-directed CD3 T-cell engager monoclonal antibody that was approved by the Food and Drug Administration (FDA) for treatment of patients with relapsed/refractory acute lymphoblastic leukemia (B-ALL) in December 2014.
- Clinical Trial Spotlight: Trial #14-195: ASTX727-01, a Phase 1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX 727 in Patients with Higher-Risk Myelodysplastic Syndromes - The DNA methyltransferase inhibitors azacitidine (Vidaza) and decitabine (Dacogen) are both FDA-approved for treatment of all French-American-British (FAB) Co-operative Group subtypes of myelodysplastic syndromes (MDS), and these drugs can alter the natural history of the disease.
- Complex Case Study: Using Genomic Testing to Tailor Treatment for Acute Myeloid Leukemia - A 69-year-old man with a long-standing history of mild normocytic anemia and thrombocytopenia presented to his hematologist in Rhode Island for a routine follow-up visit and was noted to have new severe pancytopenia.
- Research Spotlight: Understanding the Heterogeneity of Myeloid Malignancies - The myeloid malignancies, including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN) are a spectrum of biologically related, but clinically heterogeneous diseases.